Thank you for getting in touch.
If you have not heard from us in the next 48 hours, do not hesitate to call us on
UK +44 (0)115 974 9000 / US +1-800-769-3518
Translational Pharmaceutics is significantly faster than traditional drug development, as proved in a recent Tufts CSDD White Paper. On average our customers save >12 months of development time. This translates into R&D cost savings of >$100 million as well as the benefit of getting products to market much sooner.
Unlike traditional drug development, Translational Pharmaceutics integrates a wide array of activities under a single service provider. This reduces the “white space” in development and shortens the times between clinical manufacturing and dosing, from months to days.
Simple or complex drug products are manufactured in real-time during the clinical study, with arising human data used to inform the composition of the next formulation to be manufactured and dosed.
Programs are led by a highly skilled cross-functional project manager and science team offering scientifically-rich decision-making to reduce the probability that a drug will fail in later stage clinical testing due to sub-optimal formulation performance.
Translational Pharmaceutics is used to advance molecules across the full development cycle, with programs delivered via all routes of administration. Key applications within development process include:
Using our Translational Pharmaceutics approach, you can streamline your management of outsourced partners. Your program will be led by a single project manager who will manage an integrated cross-functional project team focused on delivering all of the components of traditional CDMO and CRO services — allowing you to capture multiple efficiencies.
by 12 months or more
>$9.5 million per month of time saved
by more than 85%
based on emerging human clinical data
to adjust formulation composition within a study
"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of the company's scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."